Combination therapy for treating metastatic prostate cancer
AssigneeProgenics Pharmaceuticals, Inc.
InventorVivien Wong
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and related methods for treating and/or identifying patients likely to respond to treatments for prostate cancer.
Claims34
A method of treating a subject with prostate specific membrane antigen (PSMA)-avid prostate cancer, the method comprising:
- administering to a subject one or more doses of I-131 1095 and administering one or more doses of enzalutamide, wherein the subject's tumor PSMA avidity, prior to the administering of the one or more doses of I-131 1095 and the administering of the one or more doses of enzalutamide, was assessed.
6-7. (canceled)
(canceled)
11-12. (canceled)
(canceled)
(canceled)
A method of treating a chemotherapeutic-naïve subject whose castration-resistant prostate cancer has progressed despite abiraterone treatment, the method comprising:
- determining PSMA-avidity of the cancer using a radiolabeled PSMA-binding agent;
- administering to a subject having a PSMA-avid cancer one or more doses of I-131 1095 and
- administering one or more doses of enzalutamide.
(canceled)
20-22. (canceled)
26-28. (canceled)
(canceled)
32-33. (canceled)
A kit comprising:
- one or more containers each containing one or more doses of I-131 1095 or components to produce I-131 1095.
35-41. (canceled)
Method of treatment management for a subject with PSMA-avid metastatic, castration resistant prostate cancer and cancer progression on prior abiraterone therapy comprising:
- a) demonstrating the subject's tumor PSMA avidity in bone lesions (SUV>1.5 SUV of liver) and/or visceral or lymph node lesions that have a long diameter of >2 cm, and
- b) providing a treatment of one or more doses of I-131 1095 and one or more doses of enzalutamide.
43-47. (canceled)
(canceled)
51-53. (canceled)
Dependencies are inferred from the claim text.